...
首页> 外文期刊>BMC Neurology >Optimization of treatment with interferon beta in multiple sclerosis. Usefulness of automatic system application criteria
【24h】

Optimization of treatment with interferon beta in multiple sclerosis. Usefulness of automatic system application criteria

机译:干扰素β治疗多发性硬化症的优化治疗。自动系统应用标准的有用性

获取原文
           

摘要

Background A software based tool has been developed (Optem) to allow automatize the recommendations of the Canadian Multiple Sclerosis Working Group for optimizing MS treatment in order to avoid subjective interpretation. Methods Treatment Optimization Recommendations (TORs) were applied to our database of patients treated with IFN β1a IM. Patient data were assessed during year 1 for disease activity, and patients were assigned to 2 groups according to TOR: "change treatment" (CH) and "no change treatment" (NCH). These assessments were then compared to observed clinical outcomes for disease activity over the following years. Results We have data on 55 patients. The "change treatment" status was assigned to 22 patients, and "no change treatment" to 33 patients. The estimated sensitivity and specificity according to last visit status were 73.9% and 84.4%. During the following years, the Relapse Rate was always higher in the "change treatment" group than in the "no change treatment" group (5 y; CH: 0.7, NCH: 0.07; p Conclusion Applying TOR at the first year of therapy allowed accurate prediction of continued disease activity in relapses and disability progression.
机译:背景技术已经开发了一种基于软件的工具(Optem),以使加拿大多发性硬化症工作组的建议自动化,以优化MS治疗,以避免主观解释。方法将治疗优化建议(TORs)应用于我们的接受IFNβ1aIM治疗的患者的数据库。在第一年评估患者的疾病活动数据,并根据TOR将患者分为2组:“改变治疗”(CH)和“不变治疗”(NCH)。然后将这些评估结果与接下来几年中疾病活动的临床观察结果进行比较。结果我们有55位患者的数据。 “改变治疗”状态分配给22例患者,“不改变治疗”分配给33例患者。根据上次访视状态,估计的敏感性和特异性分别为73.9%和84.4%。在接下来的几年中,“改变治疗”组的复发率始终高于“不变治疗”组(5年; CH:0.7,NCH:0.07; p结论在允许治疗的第一年使用TOR准确预测疾病复发和残疾进展中持续的疾病活动。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号